Chesapeake Asset Management’s ProShares UltraShort NASDAQ Biotechnology BIS Stock Holding History

Chesapeake Asset Management’s Portfolio BIS Stock Details BIS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-3,970	Closed	-$912K	–	63
2015 Q4	$912K	Sell	3,970 -30	-0.8%	-$7.71K	0.7%	42
2015 Q3	$1.23M	Hold	4,000	–	–	1.05%	34
2015 Q2	$919K	Buy	+4,000	New	+$992K	0.67%	39

Other funds holding BIS

AAP

Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Chesapeake Asset Management's BIS Position: Q1 2016 in Review

Chesapeake Asset Management sold out of ProShares UltraShort NASDAQ Biotechnology (BIS) in Q1 2016, closing a stake of 3,970 shares — an estimated $912K sold.

Chesapeake Asset Management first reported a position in BIS in Q2 2015 and held it in 3 quarters. The position peaked at $1.23M in Q3 2015. 14 funds tracked by Wall St. Rank hold BIS as of Q1 2016.

Chesapeake Asset Management reported no remaining ProShares UltraShort NASDAQ Biotechnology position as of Q1 2016 after selling out during the quarter.
Chesapeake Asset Management sold 3,970 ProShares UltraShort NASDAQ Biotechnology shares in Q1 2016, an estimated $912K.
Chesapeake Asset Management first reported a position in ProShares UltraShort NASDAQ Biotechnology in Q2 2015 and held it in 3 quarters.
Chesapeake Asset Management's ProShares UltraShort NASDAQ Biotechnology position peaked at $1.23M in Q3 2015.
14 funds tracked by Wall St. Rank held ProShares UltraShort NASDAQ Biotechnology as of Q1 2016.

Based on Chesapeake Asset Management's 13F filing for Q1 2016, filed 10 May 2016.